Short Squeeze? Small Biotech- ACRX
After getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9 is a real possibility in a short amount of time. Two analysts have a hold rating while seven analysts have a buy rating including Jefferies Group that has a price target of $16.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.